These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1004531)

  • 21. Testing of drug delivery systems for use in the treatment of narcotic addiction.
    Reuning RH; Malspeis L; Frank S; Notari RE
    Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):43-5. PubMed ID: 823438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of information in naltrexone study.
    Rastegar DA
    Arch Gen Psychiatry; 2007 Jul; 64(7):865; author reply 865. PubMed ID: 17606820
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of synthetic polypeptides in the preparation of biodegradable delivery vehicles for narcotic antagonists.
    Sidman KR; Arnold DL; Steber WD; Nelsen L; Granchelli FE; Strong P; Sheth SG
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):33-8. PubMed ID: 1234983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of injectable microcapsules for use in the treatment of narcotic addiction.
    Thies C
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):19-20. PubMed ID: 1241971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained release injectable naltrexone microcapsules.
    Nuwayser ES; DeRoo DJ; Balskovich PD; Tsuk AG
    NIDA Res Monogr; 1990; 105():532-3. PubMed ID: 1908558
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-acting narcotic antagonist complexes.
    Gray AP; Guardina WJ
    Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):21-6. PubMed ID: 967231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants.
    Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson RC
    Addict Biol; 2004 Mar; 9(1):67-72. PubMed ID: 15203441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants.
    Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson R; O'Neil P
    Addict Biol; 2004 Mar; 9(1):59-65. PubMed ID: 15203440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New drug formulations as the result of recent technological development efforts].
    Speiser P
    Acta Pharm Suec; 1973 Nov; 10(5):381-400. PubMed ID: 4765583
    [No Abstract]   [Full Text] [Related]  

  • 30. A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant.
    Iyer SS; Barr WH; Dance ME; Coleman PR; Karnes HT
    Int J Pharm; 2007 Aug; 340(1-2):104-18. PubMed ID: 17482393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assays for narcotic antagonist activity in rodents.
    Pierson AK
    Adv Biochem Psychopharmacol; 1973; 8(0):245-61. PubMed ID: 4152786
    [No Abstract]   [Full Text] [Related]  

  • 32. Biodegradable drug delivery systems based on aliphatic polyesters: application to contraceptives and narcotic antagonists.
    Pitt CG; Marks TA; Schindler A
    NIDA Res Monogr; 1981; 28():232-53. PubMed ID: 6791007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases.
    Brewer C
    Addict Biol; 2002 Jul; 7(3):321-3. PubMed ID: 12126492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant.
    Iyer SS; Barr WH; Karnes HT
    Int J Pharm; 2007 Aug; 340(1-2):119-25. PubMed ID: 17482777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel depots of buprenorphine have a long-acting effect for the management of physical dependence to morphine.
    Liu KS; Kao CH; Liu SY; Sung KC; Kuei CH; Wang JJ
    J Pharm Pharmacol; 2006 Mar; 58(3):337-44. PubMed ID: 16536900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic effects of select narcotic antagonists in mice.
    Nuite JA; Harris LS
    Adv Biochem Psychopharmacol; 1973; 8(0):417-25. PubMed ID: 4794888
    [No Abstract]   [Full Text] [Related]  

  • 38. An improved long-acting delivery system for narcotic antagonists.
    Misra AL; Pontani RB
    NIDA Res Monogr; 1981; 28():254-64. PubMed ID: 6791009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of depot naltrexone under legal coercion: the case for caution.
    Hall W; Capps B; Carter A
    Addiction; 2008 Dec; 103(12):1922-4. PubMed ID: 19469728
    [No Abstract]   [Full Text] [Related]  

  • 40. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.
    Carreño JE; Alvarez CE; Narciso GI; Bascarán MT; Díaz M; Bobes J
    Addict Biol; 2003 Dec; 8(4):429-38. PubMed ID: 14690879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.